Advertisement

Cutaneous Leishmaniasis

  • Michal Solomon
  • Eli Schwartz
Chapter

Abstract

Leishmaniasis is a parasitic disease transmitted by sandflies infected with the protozoa Leishmania. Cutaneous leishmaniasis is endemic in 88 countries worldwide and affects an estimated 12 million people.

There are several clinical forms of leishmaniasis, mainly: Cutaneous leishmaniasis (CL), Muco-cutaneous leishmaniasis (MCL) and Visceral leishmaniasis. The clinical manifestation of the infection depends on the species of Leishmania, which varies with geographical area and the host’s immune response.

Based on its geographical distribution, cutaneous leishmaniasis can be divided into: Old World (including, the Middle East, Southern Europe, parts of South-West Asia and Africa) and New World leishmaniasis (from Southern USA through Latin America to Argentina).

Most studies of CL and MCL provide scarce information regarding gender and leishmania infection. It is estimated that leishmaniasis is more common in males. In recent studies in Israel, we also found that among our returning-travelers with New- World CL illness, males were highly representative (83%). However, performing a population-based survey in endemic areas of Old-World CL in Israel demonstrated that the infection rate was similar between males and females. Thus, it may be postulated that there is no real gender difference in leishmanial infection, but infections are more commonly seen in men because of more risk-taking behaviors and risky travel to more remote destinations, where the chance of acquiring tropical diseases is higher. Additionally, men may be less likely to adhere to preventive measures and therefore, are at an increased risk of contracting disease.

Keywords

Cutaneous leishmaniasis Mucocutaneous Leishmaniasis Leishmanis major Leishmania tropica L. aethiopica L. infantum Leishmania braziliensis Gender 

References

  1. 1.
    Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191–9.CrossRefGoogle Scholar
  2. 2.
    Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016;63:1539–57.CrossRefGoogle Scholar
  3. 3.
    Solomon M, Greenberger S, Baum S, Pavlotsky F, Barzilai A, Schwartz E. Unusual forms of cutaneous leishmaniasis due to Leishmania major. J Eur Acad Dermatol Venereol. 2016;30:1171–5.CrossRefGoogle Scholar
  4. 4.
    Herwaldt BL, Stokes SL, Juranek DD. American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med. 1993;118:779–84.CrossRefGoogle Scholar
  5. 5.
    Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis. 2006;6:342–9.CrossRefGoogle Scholar
  6. 6.
    Faber WR, Oskam L, van Gool T, et al. Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol. 2003;49:70–4.CrossRefGoogle Scholar
  7. 7.
    Chargui N, Bastien P, Kallel K, et al. Usefulness of PCR in the diagnosis of cutaneous leishmaniasis in Tunisia. Trans R Soc Trop Med Hyg. 2005;99:762–8.CrossRefGoogle Scholar
  8. 8.
    Andrade-Narvaez FJ, Medina-Peralta S, Vargas-Gonzalez A, Canto-Lara SB, Estrada-Parra S. The histopathology of cutaneous leishmaniasis due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Rev Inst Med Trop Sao Paulo. 2005;47(4):191.CrossRefGoogle Scholar
  9. 9.
    Marfurt J, Niederwieser I, Makia ND, Beck HP, Felger I. Diagnostic genotyping of old and new world leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis. 2003;46:115–24.CrossRefGoogle Scholar
  10. 10.
    Van der Auwera G, Maes I, De Doncker S, et al. Heat-shock protein 70 gene sequencing for Leishmania species typing in European tropical infectious disease clinics. Euro Surveill. 2013;18:20543.CrossRefGoogle Scholar
  11. 11.
    Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol. 2006;44:1435–9.CrossRefGoogle Scholar
  12. 12.
    Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004;53:158–66.CrossRefGoogle Scholar
  13. 13.
    el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of old world cutaneous leishmaniasis caused by leishmania major: a double-blind control study. J Am Acad Dermatol. 1992;27:227–31.CrossRefGoogle Scholar
  14. 14.
    Solomon M, Baum S, Barzilai A, Pavlotsky F, Trau H, Schwartz E. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol. 2009;23:1189–92.CrossRefGoogle Scholar
  15. 15.
    Faris RM, Jarallah JS, Khoja TA, al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol. 1993;32:610–2.CrossRefGoogle Scholar
  16. 16.
    Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296–306.CrossRefGoogle Scholar
  17. 17.
    Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol. 2011;25:973–7.CrossRefGoogle Scholar
  18. 18.
    van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis. 2010;50:80–3.CrossRefGoogle Scholar
  19. 19.
    Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol. 2013;68:284–9.CrossRefGoogle Scholar
  20. 20.
    Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002;35:261–7.CrossRefGoogle Scholar
  21. 21.
    Jansen A, Stark K, Schneider T, Schoneberg I. Sex differences in clinical leptospirosis in Germany: 1997–2005. Clin Infect Dis. 2007;44:e69–72.CrossRefGoogle Scholar
  22. 22.
    Schlagenhauf P, Chen LH, Wilson ME, et al. Sex and gender differences in travel-associated disease. Clin Infect Dis. 2010;50:826–32.CrossRefGoogle Scholar
  23. 23.
    Solomon M, Fucs I, Glazer I, Schwartz E. Gender and Cutaneous Leishmaniasis. Submitted for publication. 2017.Google Scholar
  24. 24.
    Solomon M, Sachar N, Pavlotzky F, et al. Mucosal leishmaniasis in travelers. In: Poster presentation at world leish 6, 2017 May 16–20; Toledo, Spain.Google Scholar
  25. 25.
    Solomon M, Benenson S, Baum S, Schwartz E. Tropical skin infections among Israeli travelers. Am J Trop Med Hyg. 2011;85:868–72.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michal Solomon
    • 1
    • 2
  • Eli Schwartz
    • 2
    • 3
  1. 1.Department of DermatologyChaim Sheba Medical CenterTel HashomerIsrael
  2. 2.The Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical CenterTel HashomerIsrael

Personalised recommendations